396 results on '"Vatsalya, Vatsalya"'
Search Results
2. Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis
3. Association of Circulating Markers of Microbial Translocation and Hepatic Inflammation with Liver Injury in Patients with Type 2 Diabetes
4. One-month assessment of Th-cell axis related inflammatory cytokines, IL-17 and IL-22 and their role in alcohol-associated liver disease
5. Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder
6. Influence of age and sex on alcohol pharmacokinetics and subjective pharmacodynamic responses following intravenous alcohol exposure in humans
7. Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease
8. Pharmacodynamic determinants of hangover: An intravenous alcohol self-administration study in non-dependent drinkers
9. Alcoholic Liver Disease
10. Linoleic Acid‐Derived Oxylipins Differentiate Early Stage Alcoholic Hepatitis From Mild Alcohol‐Associated Liver Injury
11. Metabolic Profiling of Bile Acids in the Urine of Patients with Alcohol‐Associated Liver Disease
12. Association of Circulating Markers of Microbial Translocation and Hepatic Inflammation with Liver Injury in Patients with Type 2 Diabetes.
13. Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis
14. Metabolic Analysis of Nucleosides/Bases in the Urine and Serum of Patients with Alcohol-Associated Liver Disease
15. Illustration of Gut–Thyroid Axis in Alcohol Use Disorder: Interplay of Gut Dysfunction, Pro-Inflammatory Responses, and Thyroid Function
16. Association of Hypomagnesemia and Liver Injury, Role of Gut-Barrier Dysfunction and Inflammation: Efficacy of Abstinence, and 2-Week Medical Management in Alcohol Use Disorder Patients
17. Theragnostic Efficacy of K18 Response in Alcohol Use Disorder with Clinically Significant Fibrosis Using Gut-Liver Axis
18. Repurposing Treatment of Wernicke–Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile
19. Diagnostic Prospectives with Tau Protein and Imaging Techniques to Detect Development of Chronic Traumatic Encephalopathy
20. Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients
21. Dysregulation in Plasma ω3 Fatty Acids Concentration and Serum Zinc in Heavy Alcohol-Drinking HCV Patients
22. Altered urinary tryptophan metabolites in alcohol‐associated liver disease
23. Keratin 18‐M65 : A biomarker for early‐stage alcohol‐associated liver disease
24. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
25. Clinical Features, Disease Modifiers, and Natural History of Alcoholic Liver Disease
26. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.
27. Keratin <scp>18‐M65</scp> : A biomarker for early‐stage alcohol‐associated liver disease
28. The Beneficial Effects of Lactobacillus GG Therapy on Liver and Drinking Assessments in Patients with Moderate Alcohol-Associated Hepatitis
29. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis
30. Probiotic‐derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation
31. Characterization of Hypomagnesemia in Alcoholic Hepatitis Patients and Its Association with Liver Injury and Severity Markers
32. Metabolomics analysis of urine from patients with alcohol-associated liver disease reveals dysregulated caffeine metabolism
33. Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder
34. Positive blood phosphatidylethanol concentration is associated with unfavorable waitlist‐related outcomes for patients medically appropriate for liver transplantation
35. Characterization of Early-Stage Alcoholic Liver Disease with Hyperhomocysteinemia and Gut Dysfunction and Associated Immune Response in Alcohol Use Disorder Patients
36. Diagnostic Prospectives with Tau Protein and Imaging Techniques to Detect Development of Chronic Traumatic Encephalopathy
37. Metabolic Analysis of Nucleosides/Bases in the Urine and Serum of Patients with Alcohol-Associated Liver Disease
38. Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease
39. Continued Education Webinar: Leveraging Novel Microbiome-related Therapies
40. Role of Zinc in the Development/Progression of Alcoholic Liver Disease
41. Metabolomics analysis of urine from patients with alcohol-associated liver disease reveals dysregulated caffeine metabolism
42. Emerging Noninvasive Biomarkers, and Medical Management Strategies for Alcoholic Hepatitis: Present Understanding and Scope
43. Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients
44. Characterization of Gut-Thyroid Axis in Alcohol Use Disorder: Role of Gut-Dysfunction, Pro-Inflammatory Responses, and Dysregulation in Thyroid-Associated Hormones
45. Illustration of Gut–Thyroid Axis in Alcohol Use Disorder: Interplay of Gut Dysfunction, Pro-Inflammatory Responses, and Thyroid Function
46. Association of Hypomagnesemia and Liver Injury, Role of Gut-Barrier Dysfunction and Inflammation: Efficacy of Abstinence, and 2-Week Medical Management in Alcohol Use Disorder Patients
47. Characterization of Gut-Thyroid Axis in Alcohol Use Disorder: Role of Gut-Dysfunction, Pro-Inflammatory Responses, and Dysregulation in Thyroid-Associated Hormones
48. Influence of Age and Sex on Alcohol Pharmacokinetics and Subjective Pharmacodynamic Responses following Intravenous Alcohol Exposure in Humans
49. Characterization of hangover following intravenous alcohol exposure in social drinkers: methodological and clinical implications
50. Illustration of a Novel Gut-Brain Axis of Alcohol Withdrawal, Withdrawal-Associated Depression, Craving and Alcohol-Severity Index in Alcohol Use Disorder Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.